Managers / Q2 2021 · view latest →

KNOTT DAVID M

CIK 0000808722

Reported Value

$281M

Q2 2021

Positions

195

Filings on Record

2019–present window

Filed

Aug 13, 2021

original filing

Summary

Knott David M reported $281M in U.S.-listed holdings across 195 positions for Q2 2021.

Its largest position, Calumet Specialty Products Partners, represents 7.6% of the portfolio.

Compared with Q1 2021, the fund opened 37 new positions and exited 19.

Portfolio Metrics

Turnover

+18.6%

vs prior filed quarter

Top-10 Concentration

+45.4%

share of reported value

Largest Position

+7.6%

Calumet Specialty Products Partners

New / Exited

37 / 19

positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value

Portfolio Composition

By security type

Common Stock · 54.6% · $154M
Other · 30.0% · $84M
MLP · 8.5% · $24M
Ltd Part · 5.9% · $17M
REIT · 0.6% · $2M
Other · 0.4% · $1M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2021 (amended baseline)

Issuer	Move	Share Δ	Shares now	Value Δ	Value now
Coliseum Acquisition Corp.	NEW	+1.49M	1.49M	+$15M	$15M
Pershing Square Holdings, Ltd	NEW	+275.0K	275.0K	+$6M	$6M
African Gold Acquistion Corp. Warrants	NEW	+463.5K	463.5K	+$5M	$5M
SPRTEUR Support.com, Inc.	NEW	+1.36M	1.36M	+$5M	$5M
B.Riley Principal 250 Merger Corp.	NEW	+527.0K	527.0K	+$5M	$5M
Twelve Seas Investment Company II	NEW	+515.0K	515.0K	+$5M	$5M
Glass Houses Acquisition Corp.	NEW	+500.0K	500.0K	+$5M	$5M
Live Oak Mobility Aquisition Corp.	NEW	+360.2K	360.2K	+$4M	$4M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2021

48 positions

Export to Excel

#	Issuer	Class	% Portfolio	Value ↓	Shares
1	Calumet Specialty Products Partners, LP	Common	7.57%	$21M	3.10M
2	APOEUR Apollo Global Management, Inc.history →	Common	6.63%	$19M	300.0K
3	FTAIEUR Fortress Trans & Infrastructure Inv. LLC history →	Common	5.94%	$17M	497.7K
4	Coliseum Acquisition Corp.	Common	5.21%	$15M	1.49M
5	GOOG Alphabet Inc-Cl C history →	Common	4.99%	$14M	5.6K
6	UPLDEUR Upland Software, Inc.history →	Common	4.39%	$12M	300.0K
7	LGND Ligand Pharmaceuticals Incorporated history →	Common	3.50%	$10M	75.0K
8	FSK FS KKR Capital Corp.history →	Common	2.68%	$8M	350.0K
9	MDWTUSD Midwest Holding Inc.history →	Common	2.30%	$6M	165.0K
10	Pershing Square Holdings, Ltd	Common	2.22%	$6M	275.0K
11	KKR KKR & Co. Inc.history →	Common	2.11%	$6M	100.0K
12	African Gold Acquistion Corp. Warrants	Common	1.84%	$5M	450.0K
13	Danimer Scientific, Inc.	Common	1.78%	$5M	200.0K
14	Twelve Seas Investment Company II	Common	1.71%	$5M	500.0K
15	Glass Houses Acquisition Corp.	Common	1.71%	$5M	500.0K
16	Kennedy-Wilson Holdings, Inc.	Common	1.48%	$4M	210.0K
17	EBC Eastern Bankshares Inc history →	Common	1.39%	$4M	190.0K
18	Live Oak Mobility Aquisition Corp.	Common	1.25%	$4M	360.2K
19	B.Riley Principal 250 Merger Corp.	Common	1.24%	$3M	350.0K
20	PFE Pfizer Inc.history →	Common	1.24%	$3M	89.0K
21	REGN Regeneron Pharmaceuticals, Inc.history →	Common	1.19%	$3M	6.0K
22	KDMN Kadmon Holdings, Inc.history →	Common	1.15%	$3M	838.2K
23	Kairos Acquisition Corp.	Common	1.14%	$3M	331.0K
24	CNST Constellation Pharmaceuticals, Inc.history →	Common	1.10%	$3M	91.9K
25	Horizon Therapeutics Public Ltd. Company	Common	1.06%	$3M	32.0K
26	BMY Bristol-Myers Squibb Company history →	Common	1.03%	$3M	43.4K
27	Glass Houses Acquisition Corp. Warrants	Common	1.02%	$3M	250.0K
28	UTH United Therapeutics Corporation	Common	0.98%	$3M	15.3K
29	XENE Xenon Pharmaceuticals Inc.	Common	0.93%	$3M	140.6K
30	CLDNEUR Eiger BioPharmaceuticals, Inc.	Common	0.87%	$2M	286.6K
31	International Gaming Technologies	Common	0.85%	$2M	100.0K
32	AB AllianceBernstein Holdings PL Unit Ltd	Common	0.81%	$2M	49.0K
33	ZGNXEUR Zogenix, Inc.	Common	0.77%	$2M	124.7K
34	AUPH Aurinia Pharmaceuticals Inc.	Common	0.76%	$2M	164.8K
35	Horizon Acquistion Corporation	Common	0.74%	$2M	210.1K
36	Avadel Pharmaceuticals plc	Common	0.73%	$2M	304.9K
37	TGTX TG Therapeutics, Inc.	Common	0.69%	$2M	50.4K
38	Tastemaker Acquisition Corp.	Common	0.69%	$2M	200.0K
39	JPM JP Morgan Chase	Common	0.69%	$2M	12.4K
40	Medicus Science Acquisition, Corp.	Common	0.69%	$2M	200.0K
41	TREUR Trillium Therapeutics Inc.	Common	0.68%	$2M	198.7K
42	Twelve Seas Investment Company II Warrants	Common	0.68%	$2M	166.7K
43	B. Riley Principal 150 Merger Corp.	Common	0.60%	$2M	173.0K
44	Kairos Acquisition Corp. Warrants	Common	0.57%	$2M	139.3K
45	ASLAN Pharmaceuticals Limited	Common	0.56%	$2M	478.2K
46	Marinus Pharmaceuticals, Inc.	Common	0.52%	$1M	81.2K
47	uniQure N.V.	Common	0.51%	$1M	46.8K
48	CHRS Coherus Biosciences, Inc.	Common	0.49%	$1M	99.7K

Filing History

Quarter	Reported Value	Positions	Filed	Type	Links
Q3 2021	$275M	197	Nov 12, 2021	13F-HR	changes · EDGAR ↗
Q2 2021	$281M	195	Aug 13, 2021	13F-HR	changes · EDGAR ↗
Q1 2021	$234M	166	May 13, 2021	13F-HR	changes · EDGAR ↗
Q4 2020	$221M	145	Feb 12, 2021	13F-HR	changes · EDGAR ↗
Q3 2020	$170M	135	Nov 13, 2020	13F-HR	changes · EDGAR ↗
Q2 2020	$183M	127	Aug 12, 2020	13F-HR	changes · EDGAR ↗
Q1 2020	$158M	156	May 13, 2020	13F-HR	changes · EDGAR ↗
Q4 2019	$247M	152	Feb 14, 2020	13F-HR	changes · EDGAR ↗
Q3 2019	$238M	157	Nov 12, 2019	13F-HR	changes · EDGAR ↗
Q2 2019	$237M	148	Aug 12, 2019	13F-HR	changes · EDGAR ↗
Q1 2019	$251M	143	May 13, 2019	13F-HR	changes · EDGAR ↗
Q4 2018	$213M	133	Feb 12, 2019	13F-HR	changes · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 1 additional manager.

DORSET MANAGEMENT CORP028-10281

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.